POSTN and asthma: The effect of lebrikizumab on asthma exacerbation in biomarker-high patients with severe asthma (periostin ≥50 ng/mL or blood eosinophils ≥300 cells/μL) was later examined in phase 3 trials, LAVOLTA I and LAVOLTA II [87].